Ibrutinib Demonstrates Continued Efficacy for CLL Patients at 3 Year Follow-up

Previous studies have demonstrated the efficacy ibrutinib (Imbruvica), an oral inhibitor of Bruton’s tyrosine kinase, has as treatment for patients with CLL. This has led to its approval by the FDA for previously treated patients with CLL and patients with CLL who have deletion 17p regardless of prior therapy. In a paper published online in Blood, a group of investigators, including Richard R. Furman, published long term follow up results from the original phase II studies of ibrutinib in patients with CLL. The paper presents results from a median three-year follow-up of 132 treatment-naive and relapsed/refractory symptomatic patients with CLL or SLL, receiving single agent ibrutinib. Longer treatment with ibrutinib was associated with improvement in response quality, durable remissions, and with diminishing toxicity and adverse side effects. For the treatment naïve group of patients, the 30 month progression free survival was 96%. For the relapsed refractory patients, the 30 month PFS was 69%, with disease progression being seen primarily in the patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease. Findings from this study provide further evidence that ibrutinib is an effective and well tolerated long-term treatment for patients with CLL.

A full listing of available CLL trials at WCMC can be found here. Please look to this space for further developments about ibrutinib and CLL trials.



Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s